A 48-year-old woman with primary biliary cholangitis (PBC) presents with progressive pruritus, jaundice, and fatigue. Liver biopsy confirms chronic cholestasis with portal inflammation and bile duct destruction. Alkaline phosphatase is 320 U/L and total bilirubin is 3.2 mg/dL. Which is the drug of choice for slowing disease progression in this patient?

Explanation

## Drug of Choice in Primary Biliary Cholangitis (PBC) **Key Point:** Ursodeoxycholic acid (UDCA) is the first-line and only FDA-approved pharmacologic therapy for PBC. It slows disease progression, improves biochemical markers, and delays the need for liver transplantation. ### Mechanism of Action of UDCA 1. **Hydrophilic bile acid**: Replaces hydrophobic, cytotoxic bile acids 2. **Reduces cholestasis**: Improves hepatic excretion of bile and reduces enterohepatic circulation 3. **Anti-inflammatory**: Decreases hepatocyte apoptosis and reduces immune-mediated injury 4. **Immunomodulatory**: Shifts T-cell response from Th1 to Th2 phenotype ### Efficacy and Clinical Outcomes **High-Yield:** UDCA at a dose of 13–15 mg/kg/day (typically 900–1200 mg/day in divided doses) improves biochemical markers (ALP, bilirubin, transaminases) and delays progression to cirrhosis and transplantation by 5–10 years in responders. **Clinical Pearl:** Response to UDCA is predicted by the **Barcelona criteria** at 12 months: - ALP < 1.67 × ULN AND - AST < 1.5 × ULN AND - Bilirubin ≤ ULN Patients meeting these criteria have significantly improved transplant-free survival. ### Comparison of Agents in PBC | Drug | Mechanism | Evidence | Role | |------|-----------|----------|------| | **UDCA** | Hydrophilic bile acid; anti-inflammatory | Level 1A; FDA-approved | First-line, standard of care | | Azathioprine | Immunosuppression | Level 2B; limited benefit | Not recommended as monotherapy | | Corticosteroids | Anti-inflammatory | Level 2B; no survival benefit | Not recommended; risk of osteoporosis | | Cyclosporine | Calcineurin inhibitor; immunosuppression | Level 2B; nephrotoxicity | Not recommended; toxicity outweighs benefit | | Obeticholic acid (OCA) | Farnesoid X receptor agonist | Level 1B; approved 2016 | Second-line for UDCA-inadequate responders | **Mnemonic — PBC First-Line Therapy:** **U-D-C-A** = Ursodeoxycholic acid is the anchor. ### Management Algorithm for PBC ```mermaid flowchart TD A[Confirmed PBC diagnosis]:::outcome --> B[Start UDCA 13-15 mg/kg/day]:::action B --> C[Assess response at 12 months]:::decision C -->|Barcelona criteria met| D[Continue UDCA]:::action C -->|Barcelona criteria NOT met| E[Add obeticholic acid or fibrate]:::action D --> F[Monitor annually]:::action E --> G[Reassess at 12 months]:::decision G -->|Improved| H[Continue combination]:::action G -->|Worsening| I[Consider liver transplant evaluation]:::urgent ``` ### Monitoring During UDCA Therapy - **Baseline and every 3–6 months**: LFTs (ALP, bilirubin, AST, ALT) - **Annually**: Ultrasound or elastography to assess for cirrhosis - **Symptom management**: Ursodeoxycholic acid does NOT relieve pruritus; use ursodeoxycholic acid + cholestyramine, rifampicin, or opioid antagonists (naltrexone) for pruritus - **Osteoporosis screening**: DEXA scan due to cholestasis-related bone loss **Warning:** Do NOT confuse UDCA (ursodeoxycholic acid, a bile acid) with ursodiol (same drug, different name) — both refer to the same agent.